NASDAQ:GNTA Genenta Science (GNTA) Stock Price, News & Analysis $0.68 -0.02 (-3.42%) As of 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Genenta Science Stock (NASDAQ:GNTA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Genenta Science alerts:Sign Up Key Stats Today's Range$0.65▼$0.7250-Day Range$0.68▼$1.6552-Week Range$0.55▼$10.00Volume90,699 shsAverage Volume53,453 shsMarket Capitalization$15.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Genenta Science S.p.A. (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on developing cell and gene therapies for cancer. The company’s approach is designed to use genetically modified hematopoietic stem cells to deliver therapeutic proteins directly within the tumor microenvironment, with the goal of improving the effectiveness and tolerability of cancer treatment. Genenta’s lead investigational program, Temferon, is an autologous stem-cell-based gene therapy intended to generate immune cells capable of producing interferon-alpha at tumor sites. The company has primarily explored Temferon in glioblastoma and other solid tumors, including settings where localized and sustained delivery of immunomodulatory agents may be beneficial. Temferon is an investigational therapy and has not been approved for commercial use. Founded in Italy, Genenta conducts its research and development activities through operations serving international clinical and biotechnology markets. The company was co-founded by Pierluigi Paracchi, who has served as its chief executive officer. Genenta’s American depositary shares began trading on the Nasdaq under the symbol GNTA in 2021.AI Generated. May Contain Errors. Read More Genenta Science Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreGNTA MarketRank™: Genenta Science scored higher than 13% of companies evaluated by MarketBeat, and ranked 843rd out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingGenenta Science has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGenenta Science has only been the subject of 1 research reports in the past 90 days.Read more about Genenta Science's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioGenenta Science has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.75% of the float of Genenta Science has been sold short.Short Interest Ratio / Days to CoverGenenta Science has a short interest ratio ("days to cover") of 2.59, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genenta Science has recently decreased by 9.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenenta Science does not currently pay a dividend.Dividend GrowthGenenta Science does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Genenta Science this week, compared to 1 article on an average week. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genenta Science insiders have not sold or bought any company stock.Percentage Held by Insiders28.99% of the stock of Genenta Science is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.13% of the stock of Genenta Science is held by institutions.Read more about Genenta Science's insider trading history. Receive GNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genenta Science and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNTA Stock News HeadlinesGenenta Science (NASDAQ:GNTA) Trading Down 10.7% - Time to Sell?September 17, 2026 | americanbankingnews.comSòphia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into OrbitSeptember 15, 2026 | globenewswire.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.September 21 at 1:00 AM | Paradigm Press (Ad)GENENTA SCIENCE SPA: Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic ArmJuly 23, 2026 | finanznachrichten.deGenenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic ArmJuly 23, 2026 | globenewswire.comGENENTA SCIENCE SPA: Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 ResultsJuly 22, 2026 | finanznachrichten.deGenenta-Backed Sòphia High Tech Reports Fiscal Year 2025 ResultsJuly 22, 2026 | globenewswire.comGenenta Science SPA ADR GNTAJuly 12, 2026 | morningstar.comMSee More Headlines GNTA Stock Analysis - Frequently Asked Questions How have GNTA shares performed this year? Genenta Science's stock was trading at $1.49 at the beginning of the year. Since then, GNTA shares have decreased by 54.6% and is now trading at $0.6772. How were Genenta Science's earnings last quarter? Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) released its earnings results on Tuesday, March, 31st. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.29. When did Genenta Science IPO? Genenta Science (GNTA) raised $28 million in an initial public offering (IPO) on Tuesday, December 14th 2021. The company issued 2,400,000 shares at a price of $10.50-$12.50 per share. How do I buy shares of Genenta Science? Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genenta Science own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genenta Science investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), PDD (PDD) and AppLovin (APP). Company Calendar Last Earnings3/31/2026Today9/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 As of 5 days ago, GNTA's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GNTA CIK1838716 Webwww.genenta.com Phone39-02-2643-4681FaxN/AEmployees9Year Founded2014Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.35 Current Ratio14.16 Quick Ratio14.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.29 per share Price / Book0.52Miscellaneous Outstanding Shares23,590,000Free Float16,752,000Market Cap$15.98 million OptionableNot Optionable Beta0.73 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:GNTA) was last updated on 9/21/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
